- Home
- FSM vs HCM Comparison
FSM vs HCM Comparison
Compare FSM & HCM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | FSM | HCM |
|---|---|---|
| Founded | 1990 | 2000 |
| Country | Canada | Hong Kong |
| Employees | N/A | 1796 |
| Industry | Precious Metals | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.5B | 2.3B |
| IPO Year | 2005 | N/A |
Fundamental Metrics
Financial Performance| Metric | FSM | HCM |
|---|---|---|
| Price | $8.45 | $11.27 |
| Analyst Decision | Buy | Sell |
| Analyst Count | 1 | 1 |
| Target Price | ★ $14.00 | $13.75 |
| AVG Volume (30 Days) | ★ 4.5M | 46.9K |
| Earning Date | 05-06-2026 | 03-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $38.01 | $20.60 |
| Revenue Next Year | N/A | $15.62 |
| P/E Ratio | $14.10 | ★ $5.49 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $6.17 | $9.77 |
| 52 Week High | $13.85 | $19.50 |
Technical Indicators
Market Signals| Indicator | FSM | HCM |
|---|---|---|
| Relative Strength Index (RSI) | 46.92 | 51.39 |
| Support Level | $8.39 | $9.77 |
| Resistance Level | $8.88 | $11.81 |
| Average True Range (ATR) | 0.31 | 0.27 |
| MACD | 0.02 | 0.07 |
| Stochastic Oscillator | 50.20 | 46.23 |
Price Performance
Historical ComparisonAbout FSM Fortuna Silver Mines Inc (Canada)
Fortuna Mining Corp is a Canadian-based precious metals mining company with mines in the Latin America and West Africa regions producing gold and silver. It operate mines in Argentina, Burkina Faso, Cote d'voire, Mexico, and Peru. The company's segment consists of Mansfield, Sango, Bateas, Corporate. The company generates the majority of its revenue from Sango segment which operates the Seguela gold mine. Geographically, the company generates the majority of its revenue from Cote d' Ivoire location.
About HCM HUTCHMED (China) Limited
HUTCHMED (China) Ltd is a biopharmaceutical company engaged in the discovery, development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. The company has a portfolio of several cancer drug candidates currently in clinical studies world-wide and an extensive commercial infrastructure in its home market, China. The company operates in two reportable segments: Oncology/Immunology and Other Ventures.